Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment

Summary

At present, there is no standard treatment plan for hepatocellular carcinoma after the progress of first-line target immunotherapy. Based on the above research background, we believe that the combination of PD-1 inhibitors and multi-target inhibitors is a promising treatment option for second-line liver cancer. Our study aims to explore the efficacy and safety of trastuzumab monoclonal antibody combined with regorafenib compared to regorafenib monotherapy for second-line treatment of advanced hepatocellular carcinoma after previous target immunotherapy progression.

Timeline

Start

2025-08

Primary completion

2026-08

Completion

2027-08

Drugs

Indications